menu search

intellia therapeutics, inc. (ntla) reports q4 loss, tops revenue estimates

intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectiv...

February 23, 2023, 10:32 am

Is intellia therapeutics (ntla) stock outpacing its medical peers this year?

Here is how intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to the...

February 22, 2023, 11:19 am

intellia: in-vivo gene editing platform continues to deliver

In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR...

December 20, 2022, 8:25 am

intellia: most advanced in a tough field

intellia is the first to show data in a tough field of medicine. The one-off offering has a sound attra...

December 20, 2022, 7:57 am

Will intellia therapeutics stock rebound after a 31% fall in a month?

intellia Therapeutic's stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CR...

December 19, 2022, 8:00 am

Ntla stock falls as intellia therapeutics announces public offering

intellia Therapeutics (NASDAQ: NTLA ) stock is falling hard on Thursday after the company announced a p...

December 1, 2022, 9:55 am

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm


Search within

Pages Search Results: